Krempa David 4
4 · Eton Pharmaceuticals, Inc. · Filed Jan 14, 2026
Insider Transaction Report
Form 4
Krempa David
Chief Business Officer
Transactions
- Tax Payment
Common Stock
[F1][F2]2026-01-14$15.62/sh−1,942$30,334→ 630,238 total - Award
Employee Stock Option (Right to Buy)
[F3]2026-01-12+40,655→ 670,893 totalExercise: $15.47Exp: 2036-01-11→ Common Stock (40,655 underlying) - Award
Restricted Stock Units
[F4][F5]2026-01-12+25,856→ 696,749 total→ Common Stock (25,856 underlying)
Footnotes (5)
- [F1]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
- [F2]The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- [F3]The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.
- [F4]Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
- [F5]The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.
Signature
/s/ James R. Gruber|2026-01-14